Oaktree Acquisition Corp. III Life Sciences (OACC) Non-Current Deffered Revenue (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (changed 0.0% YoY), and the FY2025 full-year result was $6.7 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $6.7 million, roughly flat from $6.7 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $6.7 million in Q4 2024, with the low at $6.7 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $6.7 million across 3 years, with a median of $6.7 million in 2024.
• The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2025 against a maximum downside of 0.0% in 2025.
• Oaktree Acquisition Corp. III Life Sciences' Non-Current Deffered Revenue stood at $6.7 million in 2024, then changed by 0.0% to $6.7 million in 2025, then changed by 0.0% to $6.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $6.7 million (Q1 2026), $6.7 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.